Report Detail

Other Global Psoriasis Drugs Market Size, Status and Forecast 2019-2025

  • RnM3386433
  • |
  • 12 July, 2019
  • |
  • Global
  • |
  • 98 Pages
  • |
  • QYResearch
  • |
  • Other

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Psoriasis Drugs Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Tumor Necrosis Factor Inhibitor
      • 1.4.3 Interleukin Inhibitors
      • 1.4.4 Others
    • 1.5 Market by Application
      • 1.5.1 Global Psoriasis Drugs Market Share by Application (2014-2025)
      • 1.5.2 Topicals
      • 1.5.3 Systemic
      • 1.5.4 Biologics
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Psoriasis Drugs Market Size
    • 2.2 Psoriasis Drugs Growth Trends by Regions
      • 2.2.1 Psoriasis Drugs Market Size by Regions (2014-2025)
      • 2.2.2 Psoriasis Drugs Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Psoriasis Drugs Market Size by Manufacturers
      • 3.1.1 Global Psoriasis Drugs Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Psoriasis Drugs Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Psoriasis Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Psoriasis Drugs Key Players Head office and Area Served
    • 3.3 Key Players Psoriasis Drugs Product/Solution/Service
    • 3.4 Date of Enter into Psoriasis Drugs Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Psoriasis Drugs Market Size by Type (2014-2019)
    • 4.2 Global Psoriasis Drugs Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Psoriasis Drugs Market Size (2014-2019)
    • 5.2 Psoriasis Drugs Key Players in United States
    • 5.3 United States Psoriasis Drugs Market Size by Type
    • 5.4 United States Psoriasis Drugs Market Size by Application

    6 Europe

    • 6.1 Europe Psoriasis Drugs Market Size (2014-2019)
    • 6.2 Psoriasis Drugs Key Players in Europe
    • 6.3 Europe Psoriasis Drugs Market Size by Type
    • 6.4 Europe Psoriasis Drugs Market Size by Application

    7 China

    • 7.1 China Psoriasis Drugs Market Size (2014-2019)
    • 7.2 Psoriasis Drugs Key Players in China
    • 7.3 China Psoriasis Drugs Market Size by Type
    • 7.4 China Psoriasis Drugs Market Size by Application

    8 Japan

    • 8.1 Japan Psoriasis Drugs Market Size (2014-2019)
    • 8.2 Psoriasis Drugs Key Players in Japan
    • 8.3 Japan Psoriasis Drugs Market Size by Type
    • 8.4 Japan Psoriasis Drugs Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Psoriasis Drugs Market Size (2014-2019)
    • 9.2 Psoriasis Drugs Key Players in Southeast Asia
    • 9.3 Southeast Asia Psoriasis Drugs Market Size by Type
    • 9.4 Southeast Asia Psoriasis Drugs Market Size by Application

    10 India

    • 10.1 India Psoriasis Drugs Market Size (2014-2019)
    • 10.2 Psoriasis Drugs Key Players in India
    • 10.3 India Psoriasis Drugs Market Size by Type
    • 10.4 India Psoriasis Drugs Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Psoriasis Drugs Market Size (2014-2019)
    • 11.2 Psoriasis Drugs Key Players in Central & South America
    • 11.3 Central & South America Psoriasis Drugs Market Size by Type
    • 11.4 Central & South America Psoriasis Drugs Market Size by Application

    12 International Players Profiles

    • 12.1 AbbVie
      • 12.1.1 AbbVie Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Psoriasis Drugs Introduction
      • 12.1.4 AbbVie Revenue in Psoriasis Drugs Business (2014-2019)
      • 12.1.5 AbbVie Recent Development
    • 12.2 Amgen
      • 12.2.1 Amgen Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Psoriasis Drugs Introduction
      • 12.2.4 Amgen Revenue in Psoriasis Drugs Business (2014-2019)
      • 12.2.5 Amgen Recent Development
    • 12.3 Johnson & Johnson
      • 12.3.1 Johnson & Johnson Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Psoriasis Drugs Introduction
      • 12.3.4 Johnson & Johnson Revenue in Psoriasis Drugs Business (2014-2019)
      • 12.3.5 Johnson & Johnson Recent Development
    • 12.4 Novartis
      • 12.4.1 Novartis Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Psoriasis Drugs Introduction
      • 12.4.4 Novartis Revenue in Psoriasis Drugs Business (2014-2019)
      • 12.4.5 Novartis Recent Development
    • 12.5 Eli Lilly & Company
      • 12.5.1 Eli Lilly & Company Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Psoriasis Drugs Introduction
      • 12.5.4 Eli Lilly & Company Revenue in Psoriasis Drugs Business (2014-2019)
      • 12.5.5 Eli Lilly & Company Recent Development
    • 12.6 AstraZeneca
      • 12.6.1 AstraZeneca Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Psoriasis Drugs Introduction
      • 12.6.4 AstraZeneca Revenue in Psoriasis Drugs Business (2014-2019)
      • 12.6.5 AstraZeneca Recent Development
    • 12.7 Celgene Corporation
      • 12.7.1 Celgene Corporation Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Psoriasis Drugs Introduction
      • 12.7.4 Celgene Corporation Revenue in Psoriasis Drugs Business (2014-2019)
      • 12.7.5 Celgene Corporation Recent Development
    • 12.8 UCB
      • 12.8.1 UCB Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Psoriasis Drugs Introduction
      • 12.8.4 UCB Revenue in Psoriasis Drugs Business (2014-2019)
      • 12.8.5 UCB Recent Development
    • 12.9 Merck
      • 12.9.1 Merck Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Psoriasis Drugs Introduction
      • 12.9.4 Merck Revenue in Psoriasis Drugs Business (2014-2019)
      • 12.9.5 Merck Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Psoriasis is a genetic condition that may not be present at birth. The condition may be triggered by certain environmental and genetic factors. Changing lifestyles of people are leading to increased alcohol consumption and smoking, unhealthy diet, and sedentary living, which makes people more prone to this condition.
      In 2018, the global Psoriasis Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of 9.2% during 2019-2025.

      This report focuses on the global Psoriasis Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Psoriasis Drugs development in United States, Europe and China.

      The key players covered in this study
      AbbVie
      Amgen
      Johnson & Johnson
      Novartis
      Eli Lilly & Company
      AstraZeneca
      Celgene Corporation
      UCB
      Merck

      Market segment by Type, the product can be split into
      Tumor Necrosis Factor Inhibitor
      Interleukin Inhibitors
      Others

      Market segment by Application, split into
      Topicals
      Systemic
      Biologics

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Psoriasis Drugs status, future forecast, growth opportunity, key market and key players.
      To present the Psoriasis Drugs development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Psoriasis Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


      Summary:
      Get latest Market Research Reports on Psoriasis Drugs . Industry analysis & Market Report on Psoriasis Drugs is a syndicated market report, published as Global Psoriasis Drugs Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Psoriasis Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,052.87
      4,579.30
      6,105.73
      3,531.07
      5,296.61
      7,062.14
      424,164.00
      636,246.00
      848,328.00
      278,733.39
      418,100.09
      557,466.78
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report